Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5724MR)

This product GTTS-WQ5724MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5724MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11527MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ8211MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ10966MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ5713MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ11493MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ14515MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ4336MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ6815MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW